Ronald J. Doll

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

31h-index3.8kcitations98works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(26), Protein Kinase Regulation and GTPase Signaling(15), Click Chemistry and Applications(11), Microtubule and mitosis dynamics(9), Advanced Breast Cancer Therapies(9)

Publications98 total

Supplementary Table 2 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Supplementary Table 1 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Supplementary Table 2 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Supplementary Table 1 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Data from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Data from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2023Open Access
Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability
Bioorganic & Medicinal Chemistry Letters·2022· 1 citedOpen Access
Structure-based drug design of clinical compound MK-8353, a novel inhibitor of ERK
Acta Crystallographica Section A Foundations and Advances·2018Open Access
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
ACS Medicinal Chemistry Letters·2018· 49 citedOpen Access
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology
Bioorganic & Medicinal Chemistry Letters·2018· 14 citedOpen Access
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor
Bioorganic & Medicinal Chemistry Letters·2018· 4 citedOpen Access
Discovery of novel chiral 3o-SMe pyrrolidine as extracellular regulated kinase (ERK) inhibitors
2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors
ACS Medicinal Chemistry Letters·2016· 17 citedOpen Access
Core modification of substituted piperidines as Novel inhibitors of HDM2–p53 protein–protein interaction
Bioorganic & Medicinal Chemistry Letters·2014· 15 citedOpen Access
Marketing für Physiotherapeuten
2013· 3 cited
Abstract 2785: Discovery of a novel HDM2 inhibitor with potent in vivo anti-tumor activity
Cancer Research·2012
Farnesyl Transferase Inhibitors
˜The œEnzymes·2011· 6 cited
PV Learning Curves: Past and Future Drivers of Cost Reduction
EU PVSEC·2011· 47 citedOpen Access
Aurora Kinase Inhibitors Based on the Imidazo[1,2-<i>a</i>]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure
Journal of Medicinal Chemistry·2010· 57 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

W. Robert Bishop(18), Paul T. Kirschmeier(17), F. George Njoroge(13), Bancha Vibulbhan(12), Amin A. Nomeir(11), Arthur G. Taveras(10), Ashit K. Ganguly(10), Stacy Remiszewski(9), Viyyoor Girijavallabhan(9), Randall R. Rossman(9), Donna Carr(9), Alan K. Mallams(8), Carmen Álvarez(8), Alan Hruza(8), V. Girijavallabhan(8), Joanne Petrin(7), Linda James(7), David Parry(6), William T. Windsor(6), Emma Lees(6)